Early Recognition of Genetic Epilepsy in Neonates (H-34852)

Early Recognition of Genetic Epilepsy in Neonates (ERGENT)

Newborn babies with seizures requiring drug treatment, and for whom routine blood and imaging tests fail to reveal an underlying cause, may qualify for free-of-charge genetic panel testing through enrollment in this study. Patients must have seizure onset by 42 weeks gestational age. A medical caregiver (M.D. or R.N.) must apply for eligibility screening via a very brief online form at www.ergent.org. For questions, please see the website and/or contact us at ergent-info@bcm.edu.